SAB Biotherapeutics (SABS) Other Non-Current Liabilities (2021 - 2026)

SAB Biotherapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 352.0% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 352.0% YoY), and the FY2025 full-year result was $5.6 million, down 11.8% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $6.1 million, up from $5.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $11.8 million in Q4 2023, with the low at $8344.0 in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $3.3 million across 5 years, with a median of $2.4 million in 2025.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 99.71% — and 2024, when it soared 75475.46%.
• SAB Biotherapeutics' Other Non-Current Liabilities stood at $320930.0 in 2022, then soared by 3568.79% to $11.8 million in 2023, then plunged by 45.74% to $6.4 million in 2024, then fell by 11.8% to $5.6 million in 2025, then rose by 8.56% to $6.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $6.1 million (Q1 2026), $5.6 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.